Starting in research in 1992 while working on his PhD thesis, Dr. Schiemann was managing a research grant including a team of lab technicians.
He joined F. Hoffmann – La Roche AG in Switzerland in 1996 as group manager in manufacturing. After successfully implementing the necessary processes Dr. Schiemann moved internally at Roche’s to lead the clinical supply packaging and labeling group. There, he streamlined the processes, upgraded the machinery park and established strategic collaborations with contractors.
In 1999 Dr. Schiemann joined PricewaterhouseCoopers’ R&D Strategy consulting group. He led several projects with large and small Pharma/Biotech companies in Europe and the US helping them to establish more robust strategies and processes, e.g. supply chain, document management, R&D strategy and supporting organizations, etc.
Dr. Schiemann returned to Roche in the US in 2003 in Clinical QA establishing a risk-based approach to planning QA activities.
In 2004, Dr. Schiemann started the Quality Risk Management (QRM) project at Roche, which was fully implemented in 2009.
End of 2011 Dr. Schiemann co-founded Widler & Schiemann AG, a Management Consulting firm specializing supporting their clients in drug development. In 2016 he founded the Chinese Affiliate of Widler & Schiemann in China to support Chinese clients of Widler & Schiemann better.
In 2018 Dr. Schiemann moved to Princeton, NJ to support US clients of Widler & Schiemann.
In 2018 he also co-founded iQure Pharma, a Biotech start up, which focusses on developing compounds for unmet medical needs. Dr. Schiemann currently also serves as Chair of the Board at iQure Pharma Inc.